Erasca Inc. has presented its latest corporate update, highlighting its commitment to advancing oncology treatments with a focus on the RAS/MAPK pathway. The company, founded by Jonathan Lim, MD, and Kevan Shokat, PhD, is leveraging its experienced leadership team and a world-class scientific advisory board to target RAS-related cancer pathways. Erasca's pipeline includes promising candidates like ERAS-0015 and ERAS-4001 aimed at tackling RASm and KRASm solid tumors, respectively. Financially, Erasca is in a strong position with $387 million in cash, cash equivalents, and marketable securities, providing a cash runway into the second half of 2028. The company was recognized as one of Fierce Biotech's 2021 "Fierce 15" most promising biotechnology companies. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.